Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexmedetomidine.

N Bhana1, K L Goa, K J McClellan

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|March 24, 2000
PubMed
Summary
This summary is machine-generated.

Dexmedetomidine, an alpha2-adrenoceptor agonist, provides effective sedation and anxiolysis in intensive care unit patients. This drug demonstrated predictable hemodynamic effects and reduced analgesic needs without causing respiratory depression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-grain scintillator screens for proton radiography.

The Review of scientific instruments·2024
Same author

Kondo quasiparticle dynamics observed by resonant inelastic x-ray scattering.

Nature communications·2022
Same author

Physics-informed machine learning for inorganic scintillator discovery.

The Journal of chemical physics·2018
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quantum critical fluctuations in the heavy fermion compound Ce(Ni0.935Pd0.065)₂Ge₂.

Journal of physics. Condensed matter : an Institute of Physics journal·2014
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Anesthesiology
  • Critical Care Medicine

Background:

  • Dexmedetomidine is a selective alpha2-adrenoceptor agonist.
  • It exhibits higher affinity for alpha2-adrenoceptors than clonidine.
  • Dexmedetomidine has demonstrated sedative, analgesic, and anxiolytic properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of dexmedetomidine for sedation in postsurgical intensive care unit patients.
  • To assess its impact on hemodynamic parameters and analgesic requirements.
  • To determine the incidence of adverse events associated with its use.

Main Methods:

  • Phase III clinical trials involving postsurgical ventilated intensive care unit patients.
  • Intravenous administration of dexmedetomidine at doses of 0.2 to 0.7 microg/kg/h.

Related Experiment Videos

  • Monitoring of hemodynamic parameters, sedation levels, analgesic requirements, and adverse events.

    • Main Results:

    • Dexmedetomidine produced clinically effective and stable sedation.
    • It significantly reduced the need for analgesics in ventilated patients.
    • Hemodynamic effects included dose-dependent decreases in blood pressure and heart rate, with reductions in plasma catecholamines.
    • No significant respiratory depression was observed after cessation of ventilation.
    • The drug was generally well tolerated, with hypotension, bradycardia, and nausea being the most frequent adverse events.

    Conclusions:

    • Dexmedetomidine is an effective agent for sedating postsurgical intensive care unit patients.
    • It offers benefits such as reduced analgesic requirements and preserved patient rousability.
    • The drug is well-tolerated, with manageable adverse events, making it a valuable option in critical care settings.